Cellular Origins, a TTP Company concentrated on enabling scalable, cost-effective, and effective manufacture of cell and gene curatives( CGTs), has moment blazoned the conformation of its Advisory Board with the appointment of four encyclopedically recognized leaders across the cell and gene remedy( CGT) and robotics sectors — Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge.
The recently formed Advisory Board will give a different range of scientific, specialized, and strategic perceptivity to support Cellular Origins ’ growth as it continues to develop its robotic platform for the scalable and cost-effective manufacture of advanced curatives, Constellation ™. Professor John Campbell is the founder of several cell remedy startups, including Resolution Rectifiers and Swarm Oncology. He brings over 30 times ’ experience in the immunology and cell remedy space, with significant moxie in process development and cell remedy manufacture. John was formerly the Director of Apkins, Cells, and Advanced Rectifiers and the National Head of Research at the Scottish National Blood Transfusion Service in Edinburgh.
Dr Matthew Li has worked in the academic and artificial biotech fields over 14 times, with a focus on bias, CGT R&D, and manufacturing. In his current part as Director of cell Therapy CMC at Tome Biosciences, as well as preliminarily at Takeda and Vor Biopharma, Matthew has been privately involved in the due industriousness, assessment, and product development of multitudinous arising CGT manufacturing technologies. Dr Paul Roberts is the founder of CMR Surgical, where his platoon developed robotic technologies enabling patient access to minimally invasive surgery. Paul has expansive experience in bringing robotics technology to request in recently regulated surroundings, having handed crucial leadership in raising the largest ever MedTech private backing round with CMR Surgical in 2021. Prior to this, Paul led and grew capabilities in complex medical device development at the Science Group PLC. Geoffrey Hodge was most recently CEO of SOTIO Biotech US and CTO of Unum rectifiers, both autologous cell remedy companies. Prior to cell remedy, Geoff was the co-founder of Xcellerex, where he was the primary innovator of the XDR single-use bioreactor and head of the CDMO biomanufacturing services business, which grew to 50M in profit previous to its accession by GE Healthcare.
Dr Edwin Stone, CEO of Cellular Origins, commented: “We are looking forward to working closely with John, Matthew, Paul and Geoff. Whilst the challenges the cell therapy industry faces are unique, there is an enormous amount to be gained by making sure we incorporate both the lessons from the journey the field has been on to date and the lessons that have been learned in other industries. I’m excited by the breadth of experience they have, having unique knowledge and experience that I’m confident will be invaluable to the Cellular Origins’ mission to develop scalable and cost-effective robotic technology for the automated manufacture of advanced therapies.”
Professor John Campbell, Advisor for Cellular Origins, said: “Cellular Origins offers a transformative solution for scalable cell therapy manufacture with their innovative robotic platform, Constellation. I look forward to joining the team as part of the Advisory Board, where my own experience and that of my colleagues on the board will support Cellular Origins through this exciting time in their development and growth.
